BioNote, Inc. (KRX:377740)
South Korea
· Delayed Price · Currency is KRW 4,925.00
-20.00 (-0.40%)
At close: Mar 27, 2025, 3:30 PM KST
BioNote Revenue
In the year 2024, BioNote had annual revenue of 102.78B KRW with 14.10% growth. BioNote had revenue of 24.74B in the quarter ending December 31, 2024, with 13.67% growth.
Revenue
102.78B
Revenue Growth
+14.10%
P/S Ratio
4.73
Revenue / Employee
344.90M
Employees
298
Market Cap
483.49B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |